SYNTHESIS AND EVALUATION OF AMINO ACID ESTER CONJUGATES OF HIV PROTEASE INHIBITOR

CHABUKSWAR AR¹, PREETI M. GANDHI²*

¹Department of Pharmaceutical Chemistry, MAEER’s Maharashtra Institute of Pharmacy, Pune, Maharashtra, India. ²Department of Pharmaceutical Chemistry, JSPM’s Jayawantrao Sawant College of Pharmacy and Research, Pune, Maharashtra, India.

Email: preetigandhi2007@gmail.com

Received: 10 April 2019, Revised and Accepted: 07 May 2019

ABSTRACT

Objective: Ester conjugates of HIV protease inhibitor, lopinavir (LP) with various amino acids were synthesized to improve its physicochemical and pharmacokinetic profile and consequently therapeutic potential.

Materials and Methods: Conjugates of LP with amino acids; glycine, alanine, valine, and serine were prepared by dicyclohexylcarbodiimide coupling method. The synthesized compounds were characterized by nuclear magnetic resonance, mass, and Fourier-transform infrared spectroscopy and evaluated for their solubility, partition coefficient, hydrolytic stability, cytotoxicity, and permeability through Caco-2 cells.

Results: Aqueous solubility studies indicated significantly better solubility profiles of all conjugates as compared to LP. With respect to hydrolysis, all the conjugates displayed higher stability under acidic conditions while undergo hydrolysis with rise in pH. Conjugates did not exhibit cytotoxicity for concentration as high as 100 μg/ml, which indicates promising therapeutic potential. Absorptive diffusion of drug across Caco-2 cell monolayers was improved by amino acid conjugation.

Conclusion: Amino acid ester conjugates of LP not only showed better solubility but also significantly higher permeability than LP. Thus, direct conjugation of L-amino acids is a viable approach to improve oral absorption and thereby oral bioavailability of protease inhibitors.

Keywords: Amino acids, Conjugates, HIV, Hydrolysis, Lopinavir, Solubility.

INTRODUCTION

Several strategies have been adopted for the effective treatment of HIV/AIDS since 1984. At present, the greatest success in the clinical management of HIV/AIDS has been observed with the use of antiretroviral drugs such as reverse transcriptase inhibitors and protease inhibitors (PIs). HIV PIs represent an important class of anti-HIV drugs in highly active antiretroviral therapy regimen. Although highly active, several unfavorable physicochemical and pharmacokinetic (PK) parameters limit their efficacy. Lopinavir (LP) is potent and one of the frequently administered PIs in the treatment of the HIV [1]. LP is classified as a BCS II drug (high permeability/low solubility). It has very poor bioavailability when administered orally which is due to low water solubility, limited intestinal uptake due to P-glycoprotein efflux and high first-pass metabolism by cytochrome P450 [2-5]. Hence, to improve bioavailability, in most of the marketed formulations, it is given in combination with low-dose ritonavir (RTV) because RT is a well-known potent inhibitor of both P-gp and CYP3A [6-8]. However, coadministration of RT with other PIs leads to major adverse effects such as rise in lipid level, glucose, as well as gastrointestinal intolerance [9]. Hence, ritonavir free formulation strategy is needed.

Various strategies have been employed to inhibit both efflux and metabolism to improve oral absorption of PIs. Most common approaches used are coadministration of P-gp and MRP2 substrates with efflux inhibitors and a non-substrate strategy involving chemical modification of compounds such that efflux/metabolism is avoided. Transporter-targeted conjugate or prodrug derivatization is one of the non-substrate strategies which involve utilization of influx transporters facilitating transport of polar nutrients such as amino acids and peptides [10,11]. This strategy has been successfully used in an attempt to increase absorption of poorly absorbed drugs such as acyclovir [12], ganciclovir [13-15], saquinavir [16], and zanamivir [17]. Conjugates can be designed by coupling amino acids/peptides to compounds in such a way that they resemble the intestinal nutrients structurally and get easily absorbed by specific carrier proteins. Additional advantage of preparing such conjugates is the formation of non-toxic nutrient molecules when prodrugs are converted to parent drug and pro-moieties. As amino acids are biocompatible and easily ionizable, they have been widely used as pro-moieties in synthesis of prodrugs [18]. In the present study, conjugates of LP with amino acids, namely glycine, alanine, valine, and serine were synthesized with a simple esterification process to examine the effect of amino acids on solubility and in circumventing P-gp-mediated cellular efflux of LP. The synthesized conjugates were characterized by spectral data (ultraviolet [UV], IR, proton magnetic resonance, and mass) and evaluated for solubility, hydrolytic stability, and cytotoxicity. Transport studies were conducted in Caco-2 cells to compare permeability of conjugates with LP since efflux proteins (Pgp and MRP2) and peptide transporters are well expressed and characterized in Caco-2 cells.

MATERIALS AND METHODS

Materials

LP was obtained from Lupin Pharma Ltd. (Pune, India). Boc amino acids, dimethylaminopyridine and N, N’-dicyclohexylcarbodiimide, as well as all other reagents and solvents were commercially procured from Loba Chemicals Pvt. Ltd. (Mumbai, India). The purity of the synthesized compounds was confirmed by thin-layer chromatography (TLC) using precoated TLC plates (Merck, 20 × 20, 60F 254). Melting points were recorded in open capillary tubes and...
are uncorrected. Fourier transform infrared (FTIR) spectra were recorded in Bruker FTIR spectrometer (Model – Alpha). 1H nuclear magnetic resonance (NMR) spectra were recorded using Bruker AVANCE III 500 MHz (AV 500) multinuclei solution NMR spectrometer using CDCl3 as the solvent and TOPSPIN 3.2 software. Electrospray ionization mass spectra were recorded on Bruker Impact II UHR-TOF mass spectrometer system by electron ionization technique. This method used in positive mode gives either (M + H) + and/or (M + Na) + signal. The UV spectrophotometer used for determining the partition coefficient and hydrolysis studies of the compounds was Shimadzu-1800 double beam spectrometer.

Methods

Synthesis of ester conjugates of lopinavir

Step I: Reaction of Boc protected amino acids with lopinavir
To a well stirred and cooled solution of LP (500 mg, 0.8 mmol) in dichloromethane, dimethylaminopyridine (190 mg, 1.6 mmol) was added to activate the secondary hydroxyl group of LP and continuously stirred for 10 min at 0°C under anhydrous conditions. Then, Boc amino acid (glycine, alanine, valine, and serine, 1.6 mmol) and N,N-dicyclohexylcarbodiimide (490 mg, 2.4 mmol) were added to the reaction mixture over 30 min. The reaction mixture was thereafter, allowed to stir at 0°C for 1 h and at room temperature for next 48 h. The reaction mixture was analyzed by TLC to ensure complete conversion of reactants to product. The mixture was filtered and after drying over Na2SO4, the solvent was evaporated under reduced pressure at room temperature.

Step II: Deprotection of the N-Boc Group
Boc amino acid LP was treated with 1:1 TFA-CH2Cl2 mixture at 0°C for about 2 h. The solvent was evaporated under reduced pressure and dried in vacuo. The crude oily product, amino acid-LP, was purified by recrystallization in cold diethyl ether. The reaction scheme for the synthesis of LP-amino acid ester conjugates is shown in Scheme 1.

Characterization of conjugates
Conjugates were characterized with FTIR, 1H NMR, and mass spectroscopy. The purity was determined using TLC and physicochemical parameters were determined.

Solubility study
Saturated solutions of drug and conjugates were prepared in distilled water in 25 mL conical flasks. The sealed flasks were placed in a mechanical shaker at room temperature (RT) for 24 h and were centrifuged for 10 min to separate undissolved conjugates. The supernatant was separated, filtered, and analyzed by UV spectrophotometer at 259 nm after appropriate dilutions. The samples were studied in triplicate and the results were presented as the mean values [19, 20].

Determination of partition coefficient
The partition coefficient of the LP and synthesized conjugates was determined by shake flask method in n-octanol and water. The drug/conjugate 10 mg was added to 10 mL of aqueous phase followed by addition of 10 mL of n-octanol. The contents were thoroughly shaken for 2 h at room temperature and left for 1 h. The conjugate concentration in aqueous and organic phase was determined by UV spectrophotometer at 259 nm and partition coefficient was calculated [21].

In vitro hydrolysis
The hydrolysis kinetics of conjugates was studied in aqueous buffer solution at pH 1.2 and pH 7.4 at 37°C using hydrochloric acid and phosphate buffer, respectively. Solutions of 10 mg of conjugate prepared in 90 mL of hydrochloric acid buffer (pH 1.2) or phosphate buffer (pH 7.4) were kept in screw-capped tubes and then placed in shaking water bath (60 rpm) at 37°C. At predetermined time points, aliquots were withdrawn from tubes and analyzed by UV spectrophotometer for the amount of drug released after the hydrolysis of prodrugs. Pseudo-first-order rate constants (Kobs) were calculated with equation, Kobs =

![Scheme 1: Scheme for synthesis of lopinavir ester conjugates. R=H, -CH2-CH (CH3)2, -CH2OH (glycine, alanine, valine, and serine)](image)

343
The mass spectroscopic analysis gives the (M + H)\(^+\) peak confirming molecular weight of the targeted compounds.

**Spectral data**

| Conjugate | Spectroscopic Data |
|-----------|--------------------|
| (S,S)-5-(2-(2,6-dimethylphenoxy)acetamido)-5-(3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamido) lopinavir serine conjugate (LPS) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) 3342.70 (N-H str. amine), 1739.34 (C = O ester), 1239.23 (C-O str. ester), 1565.58 (C = C str. aromatic) 1448.16 (C-H str. aromatic), 1256.02 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) | %Yield: 76.5; Low melting solid; UV (λmax): (MeOH) 260 nm, IR (cm\(^{-1}\)): 3342.70 (N-H str. amine), 1738.94 (C = O ester), 1239.40 (C-O str. ester), 1565.49 (C = C str. aromatic) 1449.78 (C-H str. aromatic), 1260.51 (C-H bend (asymmetric bend,-CH3)) 3320.42 (N-H str. amine), 2928.76 (C-H str. aromatic), 1750.03 (C = O ester), 1264.39 (C-O str. ester), 1548.08 (C = C str. aromatic) 1448.76 (C-H str. aromatic), 1250.56 (C-H bend (asymmetric bend,-CH3)) |

The permeability coefficients were calculated according to the following equation:

\[ P_{\text{app}} = \frac{\Delta Q}{\Delta t} \times \frac{1}{A \times C_i} \]

Where, \(\Delta Q/\Delta t\) is the rate of drug/conjugate flux (mol/s) from donor into the receiver compartment at steady state, A – the monolayer area (cm\(^2\)), and \(C_i\) – the initial concentration of drug/conjugate in apical compartment (mg/mL) [25].

**Statistical analysis**

Solubility, buffer stability, and cytotoxicity study results were expressed as mean ± standard deviation; Student’s t-test was applied to determine the statistical significance among groups. P<0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

**Chemistry**

The LP ester conjugates were synthesized by the dicarloxykcarbodiimide coupling method. Amino acids, glycine, alanine, valine, and serine were identified as carriers for the synthesis of LP ester conjugates. All conjugates were subjected to solubility, physicochemical characterization, and hydrolytic studies. Purity of the synthesized prodrugs was ascertained by melting point and TLC. The physicochemical characterization and hydrolytic studies. Purity of the synthesized prodrugs was ascertained by melting point and TLC. The mass spectroscopic analysis gives the (M + H)\(^+\) peak confirming molecular weight of the targeted compounds.

The mass spectroscopic analysis gives the (M + H)\(^+\) peak confirming molecular weight of the targeted compounds.
Cytotoxicity studies
Cytotoxicity of conjugates was determined in Caco-2 cells with MTT assay to check their safety. Results obtained from this study are demonstrated in Fig. 1. Blank medium (without any drug) was used as control. Doxorubicin was used as positive control. DMSO concentration was kept < 0.1% in all the samples. Conjugates did not exhibit any cell cytotoxicity up to a concentration of 100 µg/ml. However, they were observed to be significantly cytotoxic at 200 µg/ml. Based on these results, to prevent cytotoxic effects of conjugates, permeability studies were carried out at concentrations of ≤50 µg/ml.

Permeability study
Human colon adenocarcinoma cell line (Caco-2) is one of most frequently used and best-established cell lines for the determination of drug permeability across intestinal membranes. Caco-2 cells have been reported to express both P-gp and peptide transporters. Hence, the permeability of LP and its ester conjugates was estimated across the apical cell layer of this cell line. Apparent permeability generated by glycine, alanine, valine, and serine conjugates of LP across Caco-2 cells in A-B direction was 4.5 × 10⁻⁵, 6.1 × 10⁻⁵, 7.0 × 10⁻⁵ and 3.9 × 10⁻⁵ cm/s, respectively, whereas for LP, it was found to be 2.9 × 10⁻⁵ cm/s. Apical-to-basolateral permeability of LPG, LPA, LPV, and LPS was about 1.6, 2.2, 2.5 and 1.4-fold higher relative to LP (Fig. 2). All the amino acid conjugates tested showed higher permeability compared to LP which may be due to their reduced recognition by efflux carriers (P-gp) compared to LP. This study also indicated that synthesized amino acid ester conjugates are good substrates for the amino acid transporters expressed on the intestinal barrier and, hence, may get translocated efficiently resulting in higher oral bioavailability.

CONCLUSION
The present study utilizes amino acids to prepare ester conjugates of LP to improve its physicochemical and PK profile and consequently therapeutic effectiveness. Direct conjugation of amino acids not only improved solubility but also led to enhancement in absorptive flux of LP across Caco-2 cells. This study confirms that the amino acid conjugation approach has the potential to improve oral absorption and thereby oral bioavailability of PIs.

AUTHORS’ CONTRIBUTIONS
Preeti Gandhi has carried out experiments and analyzed results. Dr. A. R. Chabukswar guided this research work. The authors are thankful to the principal and management of JSPM’s Jaywantrao Sawant College of Pharmacy and Research and Maharashtra Institute of Pharmacy, Pune, for providing necessary facilities to carry out present research work.
CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003;63:769-802.
2. Tippahbhotla SK, Thudi NR, Raghuvasani R, Khrouro AH, Gurule S, Mishra S, et al. A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules. Int J Clin Pharmacol Ther 2008;46:204-10.
3. Hsu A, Isaacson J, Brun S, Bernstein B, Lani W, Bertz R, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:350-9.
4. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor. Int J Pharm 2008;359:139-47.
5. Kumar GN, Jayanti VK, Johnson MK, Uchic J, Thomas S, Lee RD, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004;21:1622-30.
6. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999;27:902-8.
7. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94.
8. Ribera E, Aznave C, Lopez RM, Diaz M, Feijoo M, Pou L, et al. Atazanavir and lopinavir/ritonavir: Pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006;20:1131-9.
9. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005;6:421-5.
10. Agarwal S, Boddu SH, Jain R, Samanta S, Pal D, Mitra AK, et al. Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 2008;359:17-14.
11. Patel M, Mandava N, Gokulgandhi M, Pal D, Mitra AK. Amino acid prodrugs: An approach to improve the absorption of HIV-1 protease inhibitor, lopinavir. Pharmaceuticals (Basel) 2014;7:433-52.
12. Dias C, Nashed Y, Atluri H, Mitra A. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. Curr Eye Res 2002;25:243-52.
13. Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER, et al. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm 2005;305:75-89.
14. Gunda S, Hariharan S, Mitra AK. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): In vivo comparative evaluation of these prodrugs with val-GCV and GCV in rabbits. J Ocul Pharmaco Ther 2006;22:465-76.
15. Majumdar S, Nashed YE, Patel K, Jain R, Itahashi M, Neumann DM, et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: In vitro and in vivo evaluations. J Ocul Pharmaco Ther 2005;21:463-74.
16. Jain R, Duvvuri S, Kansara V, Mandava NK, Mitra AK. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm 2007;336:233-40.
17. Gupta SV. Enhancing the intestinal membrane permeability of zanamivir: A carrier mediated prodrug approach. Mol. Pharm 2011;8:2358-67.
18. Urendran V, Singh A, Sampathkumar PK. Synthesis and characterization of novel amino acid prodrug of famotidine. Int J Pharm Sci 2015;7:403-8.
19. Mahtlouz NM, Hassan MA. Synthesis, chemical and enzymatic hydrolysis and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility. J Pharm Pharmacol 2001;53:841-48.
20. Shah N, Seth AK, Balaraman R. Bioavailability enhancement of poorly soluble raloxifene by designing inclusion complex with β-cyclodextrin. Int J Pharm Sci 2015;7:205-11.
21. Aggarwal AK, Gupta M. Solubility and solution stability studies of lopinavir/ritonavir capsules. Int J Clin Pharmacol Ther 2008;46:204-10.
22. Zhao X, Tao X, Wei D, Song Q. Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates. Eur J Med Chem 2012;58:1319-27.
23. Dhokchawle BV, Bhandari AB. Synthesis, hydrolysis kinetics and pharmacological evaluation of aceclofenac prodrugs. Antiinflamm Antiallergy Agents Med Chem 2015;13:188-94.
24. Joshi G, Kumar A, Sawant K. Bioavailability enhancement, caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug Deliv 2016;23:3492-504.
25. Senanayake TH, Warren G, Wei X, Vinogradov SV. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Control Release 2013;167:200-9.